IMMVF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.04
Previous CloseN/A
Volume150.00
Average Volume (3M)0.00
Market Cap
$4.88M
Enterprise Value$99.54M
Total Cash (Recent Filing)$34.90M
Total Debt (Recent Filing)$3.27M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding672,666,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market Cap20.41
Enterprise Value/Revenue82.27
Enterprise Value/Gross Profit-6.28
Enterprise Value/Ebitda-1.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$303.11K
Bulls Say, Bears Say
Bulls Say
Clinical ValidationThe test’s reported sensitivity and specificity support clinical credibility for earlier pancreatic cancer detection. This evidence may strengthen physician adoption, payer submissions, and partnerships as Immunovia builds a durable position in high-risk surveillance.
Commercial TractionGrowing use among major cancer centers and a broader engaged pipeline indicate that the product is gaining access to influential clinical customers. Converting this interest into repeat ordering could create a stronger commercial base and improve market position over time.
Low LeverageLow financial leverage limits interest and refinancing pressure compared with a highly indebted company. This gives management greater balance-sheet flexibility to pursue clinical development, reimbursement work, and commercialization, although operating cash burn still requires attention.
Bears Say
Deep UnprofitabilityThe revenue base remains far too small to support the current cost structure, with deeply negative gross profit and substantial net losses. Until commercial scale improves materially, profitability and shareholder value remain exposed to continued operating losses.
Cash Burn And Financing NeedHeavy cash consumption reduces the time available to reach commercial scale and makes additional capital or partnerships important. Financing needs can constrain strategic flexibility and may interrupt development if funding is not secured on acceptable terms.
Reimbursement UncertaintyUncertain reimbursement rates and coverage criteria make future revenue conversion difficult to forecast. If payers delay decisions or restrict coverage to a narrow population, adoption may remain concentrated and the test may take longer to offset commercialization costs.
Immunovia AB News
IMMVF FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was $0.01 and its highest was $0.04 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is $4.88M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 06, 2026. The company reported -$0.003 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.001.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is >-0.01.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -$0.003 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in IMMVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMVF Company Deck
IMMVF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of meaningful commercial and clinical progress alongside material operational and financing risks. Key positives include very strong percentage revenue growth, robust clinical performance (83.3% sensitivity, ~92% specificity), major center uptake, and an expanding engaged pipeline. Offsetting these are still-modest absolute revenues, an increased operating loss due to higher personnel and study spending, limited cash runway into Q4 2026 requiring near-term financing or partnerships, and uncertainty around reimbursement levels and timing. Overall, the company is showing clear early commercial and clinical traction but remains exposed to execution and funding risks as it scales.View all IMMVF earnings summariesTechnical Analysis
Biosergen AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―